How doctors use targeted drugs for a rare brain tumor
Original title: Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors looked back at records of people already treated, not a planned trial.
The short version
In most of these patients, the tumor got smaller with targeted drugs.
What was studied. Doctors looked back at patient records from several hospitals in one research group. They studied 19 people with a rare brain tumor called papillary craniopharyngioma, all with a gene change called BRAF V600E, who took targeted drugs.
What they found. The tumor got at least a little smaller in 13 of 19 people, or 72.2%. No one's tumor grew while on the drugs. Mild to moderate side effects happened in 79% of cases, and nine people (47.4%) stopped the drugs at some point. People who took one drug alone had no serious side effects, compared to 28.5% of those who took two drugs.
What this means, and what it doesn't
What it could mean: For this rare tumor, these drugs helped shrink the tumor in many people. Some people did well without radiation. Taking one drug alone may cause fewer serious side effects than taking two. If you have this tumor, ask your doctor whether gene testing and these drugs fit your case.
What it doesn't mean: This is not a cure, and it does not change care for other brain tumors. This was not a planned trial. Doctors just looked back at records of people already treated. Only 19 people were included, and they were not followed for many years. So this cannot prove that one treatment plan is better than another. The authors say these options need more study.
Source: PubMed, August 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.